Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion type Assertion NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_head.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion description "[Patients with mutated and wild-type (WT) TET2 had mostly comparable pretreatment characteristics, except for lower hemoglobin, better cytogenetic risk and longer MDS duration before AZA in TET2 mutated patients (P=0.03, P=0.047 and P=0.048, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_provenance.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion evidence source_evidence_literature NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_provenance.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion SIO_000772 21494260 NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_provenance.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion wasDerivedFrom befree-20140225 NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_provenance.
- NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_assertion wasGeneratedBy ECO_0000203 NP872470.RAfuWD0G-5Q3qb9fzspCfMDTPJHFOvZ5MtLb5fplQmwOI130_provenance.